Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly's operating income rose by 75%. For the three-month period ended June 30, Lilly's revenue increased by 36% year over year to $11.3 billion, thanks in large part to the growth in Mounjaro ...

Eli Lilly (LLY 2.29%) has been on an epic run of late. Thanks to the excitement over its Alzheimer's disease and weight-loss assets, Lilly's shares have clobbered the broader markets over the past ...